Reprogramming
fat cells to fuel
health & longevity.
We’re pioneering disease-targeting therapies for obesity, liver disease and chronic inflammation by transforming white fat on a cellular level.
Focus
We’re reprogramming white fat into brown fat to combat serious, global diseases.
At MetaShape Pharma, our purpose is to help people live their best lives by turning back the clock on their fat cells. Our drug, MS 001, has the potential to be effective across a range of indications.
Obesity
Non-Alcoholic Steatohepatitis (NASH)
Immune-Mediated Disease
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Lower Urinary Tract Dysfunction
Cancer-Related Obesity
Science
Understanding the Nature of Fat Cells
White Fat Cells
increase with age
Powerful endocrine organ
Cause high blood glucose & resistance to insulin
Raise cholesterol & risk of heart disease
Cause inflammation
Brown Fat Cells
decrease with age
Healthy type of body fat
Efficient at burning energy
Aid cardio-metabolic health
Control blood sugar
Discovering the Snowball Effect on Fat Transformation
A groundbreaking discovery published in the journal, Nature 1 2, has shown that when brown fat cells die, they release the purine nucleoside and signaling molecule inosine, which induces the “browning” of white adipose tissue via snowball kinetics. This information has provided us the missing link that has long prevented brown-fat therapies in succeeding.
MS 001 Therapy Effectively Stimulates Reprogramming of White Fat Cells
MS 001 is an orally administered purine nucleoside phosphorylase (PNP) inhibitor that elevates very high levels of inosine, the key metabolite for transforming white fat into brown fat. MS 001 is proven to be a much more effective way to internally trigger cell transformation, as opposed to simply administering inosine.
Explore How MS 001 Works at a Cellular Level
OBESITY
We’re disrupting the treatment of obesity.
More than 1 billion people worldwide are obese.
World Health OrganizationIt’s time to tackle the root cause of obesity with MS 001.
MS 001 Pre-Clinical Results on Obesity
MS 001 increases inosine signalling, which leads to browning of white fat. This transformation fires up energy consumption and shrinks body fat for:
- Healthy and sustained weight loss.
In addition, MS 001:
- Normalizes blood glucose
- Lowers serum cholesterol
- Reduces uric acid
MS 001 has been shown to be safe and well-tolerated in earlier Phase II human studies.
Pipeline
Broad Application for Future Growth
Our mode of action has applications in additional indications and risk-mitigated development pathways
About Us
Deep Experience in Pharmaceutical Science
Thomas Mehrling, MD, PhD
Chief Executive Officer
Shanta Bantia, PhD
Chief Scientific Officer
Jessica Kourniakti, DPhil
Chief Operating Officer
Randall Riggs, MBA
Chief Business Officer
Request Our One-Pager
MetaShape’s Trajectory and 5-Year Development Plan
Help us usher in this groundbreaking drug and improve the lives of millions.
